The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its key gene therapy treatment appeared at ...

Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: ...

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

One of biotech’s highest fliers, Sarepta Therapeutics, lost more than a third of its market value on Friday after executives said that one of its experimental gene-replacement therapies was linked to ...

Sarepta Therapeutics (NASDAQ:SRPT) has always been pushing the edge of biotech by advancing therapies for several rare diseases using RNA therapies, gene therapies, and gene editing.Not only has ...

At the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...

- Sarepta to host investor call on June 16, 2025, at 8:00 am Eastern time. ... Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, ...